N Engl J Med. 2021 Apr 1;384(13):1269-1271.
PMID: 33789017 DOI: 10.1056/NEJMe2101983
Excerpt from conclusion:
CheckMate 577 is a practice-changing trial in the treatment of esophageal cancer. Although overall survival data are not mature, the doubling of median disease-free survival will almost certainly translate into an overall survival benefit. The trial shows the first true advance in the adjuvant therapy of esophageal cancer in recent years and will become a new standard of care. However, despite the improvement observed, most patients will not gain benefit from adjuvant therapy with nivolumab. More contemporary biomarkers, including the presence of persistent circulating tumor DNA after surgery, should be explored to better define high-risk populations and potentially monitor patients receiving adjuvant therapy.